Shi Shali, Yu Xiaoyan, Gao Yimin, Xue Binbin, Wu Xinjiao, Wang Xiaohong, Yang Darong, Zhu Haizhen
Department of Molecular Medicine, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, Changsha, China.
J Virol. 2014 Feb;88(4):1990-9. doi: 10.1128/JVI.03312-13. Epub 2013 Dec 4.
Hepatitis C virus (HCV) core protein is essential for virus assembly. HCV core protein was expressed and purified. Aptamers against core protein were raised through the selective evolution of ligands by the exponential enrichment approach. Detection of HCV infection by core aptamers and the antiviral activities of aptamers were characterized. The mechanism of their anti-HCV activity was determined. The data showed that selected aptamers against core specifically recognize the recombinant core protein but also can detect serum samples from hepatitis C patients. Aptamers have no effect on HCV RNA replication in the infectious cell culture system. However, the aptamers inhibit the production of infectious virus particles. Beta interferon (IFN-β) and interferon-stimulated genes (ISGs) are not induced in virally infected hepatocytes by aptamers. Domains I and II of core protein are involved in the inhibition of infectious virus production by the aptamers. V31A within core is the major resistance mutation identified. Further study shows that the aptamers disrupt the localization of core with lipid droplets and NS5A and perturb the association of core protein with viral RNA. The data suggest that aptamers against HCV core protein inhibit infectious virus production by disrupting the localization of core with lipid droplets and NS5A and preventing the association of core protein with viral RNA. The aptamers for core protein may be used to understand the mechanisms of virus assembly. Core-specific aptamers may hold promise for development as early diagnostic reagents and potential therapeutic agents for chronic hepatitis C.
丙型肝炎病毒(HCV)核心蛋白对于病毒组装至关重要。表达并纯化了HCV核心蛋白。通过指数富集配体系统进化技术筛选出针对核心蛋白的适配体。对核心适配体检测HCV感染的能力及其抗病毒活性进行了表征,并确定了其抗HCV活性的机制。数据表明,筛选出的针对核心蛋白的适配体不仅能特异性识别重组核心蛋白,还能检测丙型肝炎患者的血清样本。适配体对感染性细胞培养系统中的HCV RNA复制没有影响。然而,这些适配体抑制感染性病毒颗粒的产生。适配体不会在病毒感染的肝细胞中诱导β干扰素(IFN-β)和干扰素刺激基因(ISG)。核心蛋白的结构域I和II参与了适配体对感染性病毒产生的抑制作用。核心蛋白内的V31A是鉴定出的主要抗性突变。进一步研究表明,适配体破坏了核心蛋白与脂滴和NS5A的定位关系,并干扰了核心蛋白与病毒RNA的结合。数据表明,针对HCV核心蛋白的适配体通过破坏核心蛋白与脂滴和NS5A的定位关系以及阻止核心蛋白与病毒RNA的结合来抑制感染性病毒的产生。核心蛋白特异性适配体可用于了解病毒组装机制。核心特异性适配体有望开发成为慢性丙型肝炎的早期诊断试剂和潜在治疗药物。